KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Common Equity: 2009-2025

Historic Common Equity for Exact Sciences (EXAS) over the last 15 years, with Sep 2025 value amounting to $2.5 billion.

  • Exact Sciences' Common Equity fell 22.09% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 22.09%. This contributed to the annual value of $2.4 billion for FY2024, which is 23.62% down from last year.
  • As of Q3 2025, Exact Sciences' Common Equity stood at $2.5 billion, which was up 1.30% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Exact Sciences' Common Equity registered a high of $3.6 billion during Q1 2021, and its lowest value of $2.4 billion during Q1 2025.
  • Moreover, its 3-year median value for Common Equity was $3.1 billion (2023), whereas its average is $2.9 billion.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 51.53% in 2021, then dropped by 23.62% in 2024.
  • Quarterly analysis of 5 years shows Exact Sciences' Common Equity stood at $3.4 billion in 2021, then dropped by 10.17% to $3.0 billion in 2022, then climbed by 3.36% to $3.1 billion in 2023, then declined by 23.62% to $2.4 billion in 2024, then dropped by 22.09% to $2.5 billion in 2025.
  • Its Common Equity stands at $2.5 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.4 billion for Q1 2025.